Short Interest in Dyadic International Inc. (NASDAQ:DYAI) Drops By 12.8%

Dyadic International Inc. (NASDAQ:DYAI) was the target of a large decrease in short interest in February. As of February 27th, there was short interest totaling 94,848 shares, a decrease of 12.8% from the February 12th total of 108,709 shares. Approximately 0.4% of the shares of the stock are sold short. Based on an average daily volume of 41,537 shares, the days-to-cover ratio is presently 2.3 days. Based on an average daily volume of 41,537 shares, the days-to-cover ratio is presently 2.3 days. Approximately 0.4% of the shares of the stock are sold short.

Dyadic International Stock Performance

Shares of Dyadic International stock opened at $0.80 on Wednesday. The stock has a market cap of $29.03 million, a price-to-earnings ratio of -3.34 and a beta of 1.29. Dyadic International has a twelve month low of $0.71 and a twelve month high of $1.48. The company’s fifty day moving average is $0.84 and its 200 day moving average is $0.95. The company has a quick ratio of 2.85, a current ratio of 2.85 and a debt-to-equity ratio of 1.92.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Dyadic International in a research note on Monday, December 29th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $3.00.

Institutional Investors Weigh In On Dyadic International

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Bank of America Corp DE raised its position in shares of Dyadic International by 16,146.7% during the fourth quarter. Bank of America Corp DE now owns 27,132 shares of the biotechnology company’s stock worth $47,000 after acquiring an additional 26,965 shares during the last quarter. Marathon Capital Management bought a new stake in Dyadic International in the third quarter valued at approximately $41,000. Geode Capital Management LLC boosted its holdings in Dyadic International by 13.7% in the fourth quarter. Geode Capital Management LLC now owns 301,673 shares of the biotechnology company’s stock valued at $284,000 after acquiring an additional 36,266 shares during the last quarter. Chapin Davis Inc. increased its position in Dyadic International by 5.6% during the 3rd quarter. Chapin Davis Inc. now owns 932,004 shares of the biotechnology company’s stock valued at $1,100,000 after purchasing an additional 49,155 shares during the period. Finally, AlphaCore Capital LLC bought a new position in Dyadic International during the 2nd quarter worth approximately $50,000. Institutional investors and hedge funds own 27.95% of the company’s stock.

About Dyadic International

Dyadic International, Inc is a biotechnology company headquartered in Jupiter, Florida, that specializes in developing and commercializing its proprietary C1 fungal-based expression platform. The company’s core business revolves around enabling efficient, scalable production of proteins and enzymes for a wide range of applications, including biopharmaceuticals, industrial enzymes, agricultural bioactives and biofuels. By leveraging its C1 system, Dyadic seeks to offer clients cost-effective, high-yield manufacturing processes that can accelerate development timelines and reduce overall production costs.

The Dyadic C1 platform is designed to produce complex proteins five to ten times faster than traditional cell culture technologies, such as CHO cells or yeast.